Component

Neuropathy Impairment Score / NIS

Neuropathy Impairment Score / NIS. Species, exposure and limitations are retained in each linked claim.

2 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. ALADIN III found an early NIS improvement, while the seven-month comparison of continued ALA versus placebo did not reach conventional significance.

    Lipoic acid → Neuropathy Impairment Score / NIS source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/ala-research/10480774.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "d28f04985ace61dd6036ea4d08d84e59c47ba587cea6438b7851e036abc1c673", "start_char": 0, "end_char": 2880, "text_sha256": "d28f04985ace61dd6036ea4d08d84e59c47ba587cea6438b7851e036abc1c673"}
    experimental_model
    ALADIN III multicenter randomized placebo-controlled trial
    exposure
    Three weeks intravenous treatment followed by six months oral ALA 600 mg three times daily or comparator sequences
    limitations
    Different route, duration and design from SYDNEY 2; preserve daily-score AUC and final-visit findings separately.
    nutrient_topic
    Alpha-lipoic acid research collection; topical membership is not evidence of a direct dietary effect. · Lipoic acid
    organism
    Human
    plain_language
    An early examination-score signal did not establish durable benefit.
    primary_references
    [ala-p10480774] Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. (1999). https://pubmed.ncbi.nlm.nih.gov/10480774/ DOI: 10.2337/diacare.22.8.1296
    tissue_or_cell_type
    509 people with type 2 diabetes and symptomatic polyneuropathy

    Alpha-lipoic acid: cofactor assembly, redox signaling and nutrient interactions (2026-09-17) · lines 1157–1168

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · ALADIN III multicenter randomized placebo-controlled trial · source_derived_draft · unverified_draft

    ### ala-aladin3-nis ALADIN III found an early NIS improvement, while the seven-month comparison of continued ALA versus placebo did not reach conventional significance. Condition category: normal nutrient_topic: Alpha-lipoic acid research collection; topical membership is not evidence of a direct dietary effect. plain_language: An early examination-score signal did not establish durable benefit. organism: Human tissue_or_cell_type: 509 people with type 2 diabetes and symptomatic polyneuropathy experimental_model: ALADIN III multicenter randomized placebo-controlled trial limitations: Different route, duration and design from SYDNEY 2; preserve daily-score AUC and final-visit findings separately. exposure: Three weeks intravenous treatment followed by six months oral ALA 600 mg three times daily or comparator sequences evidence_span: {"source_cache": "artifacts/ala-research/10480774.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "d28f04985ace61dd6036ea4d08d84e59c47ba587cea6438b7851e036abc1c673", "start_char": 0, "end_char": 2880, "text_sha256": "d28f04985ace61dd6036ea4d08d84e59c47ba587cea6438b7851e036abc1c673"} [ala-p10480774] Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. (1999). https://pubmed.ncbi.nlm.nih.gov/10480774/ DOI: 10.2337/diacare.22.8.1296
    Complete structured claim and evidence

  2. NATHAN 1 reported improvement in selected secondary impairment scores despite the nonsignificant primary endpoint.

    Lipoic acid → Neuropathy Impairment Score / NIS source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/ala-research/21775755.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "39d87bd4d8c5b80564bce0fd04c3c62d00b5c76e8edac29d94ff176b97bcc1f9", "start_char": 0, "end_char": 1839, "text_sha256": "39d87bd4d8c5b80564bce0fd04c3c62d00b5c76e8edac29d94ff176b97bcc1f9"}
    experimental_model
    NATHAN 1 randomized placebo-controlled trial
    exposure
    ALA 600 mg/day for four years
    limitations
    Primary endpoint and secondary analyses must remain distinct; lack of expected placebo deterioration complicated interpretation.
    nutrient_topic
    Alpha-lipoic acid research collection; topical membership is not evidence of a direct dietary effect. · Lipoic acid
    organism
    Human
    plain_language
    Some examination measures favored treatment, but they do not replace the main result.
    primary_references
    [ala-p21775755] Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. (2011). https://pubmed.ncbi.nlm.nih.gov/21775755/ DOI: 10.2337/dc11-0503
    tissue_or_cell_type
    460 people with mild-to-moderate diabetic polyneuropathy

    Alpha-lipoic acid: cofactor assembly, redox signaling and nutrient interactions (2026-09-17) · lines 1183–1194

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · NATHAN 1 randomized placebo-controlled trial · source_derived_draft · unverified_draft

    ### ala-nathan1-secondary-nis NATHAN 1 reported improvement in selected secondary impairment scores despite the nonsignificant primary endpoint. Condition category: normal nutrient_topic: Alpha-lipoic acid research collection; topical membership is not evidence of a direct dietary effect. plain_language: Some examination measures favored treatment, but they do not replace the main result. organism: Human tissue_or_cell_type: 460 people with mild-to-moderate diabetic polyneuropathy experimental_model: NATHAN 1 randomized placebo-controlled trial limitations: Primary endpoint and secondary analyses must remain distinct; lack of expected placebo deterioration complicated interpretation. exposure: ALA 600 mg/day for four years evidence_span: {"source_cache": "artifacts/ala-research/21775755.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "39d87bd4d8c5b80564bce0fd04c3c62d00b5c76e8edac29d94ff176b97bcc1f9", "start_char": 0, "end_char": 1839, "text_sha256": "39d87bd4d8c5b80564bce0fd04c3c62d00b5c76e8edac29d94ff176b97bcc1f9"} [ala-p21775755] Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. (2011). https://pubmed.ncbi.nlm.nih.gov/21775755/ DOI: 10.2337/dc11-0503
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards